Cellebrite DI (NASDAQ:CLBT) Given New $15.00 Price Target at Lake Street Capital

Key Points

• Lake Street Capital cut Cellebrite DI’s price target to $15 from $21 but maintained a Buy rating, implying about 34.7% upside from the $11.14 closing price. Other analysts also reduced targets, though the stock retains a Moderate Buy consensus with an average target of $16.70.
• Cellebrite’s quarterly EPS of $0.11 beat the $0.05 consensus estimate, but revenue of $131.14 million slightly missed expectations. Investors remain concerned about weaker forward revenue guidance and slower projected recurring-revenue growth.
• Insiders have sold nearly 298,000 shares worth approximately $4.6 million over the past 90 days, including significant sales by the CFO and outgoing CEO. Institutional investors own 45.88% of the company.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its price target dropped by stock analysts at Lake Street Capital from $21.00 to $15.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Lake Street Capital's price objective would indicate a potential upside of 34.65% from the company's previous close.

A number of other equities research analysts have also recently commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research note on Friday. DA Davidson lowered their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating on the stock in a report on Friday. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday. Finally, Weiss Ratings raised shares of Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, May 18th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.70.

Cellebrite DI Stock Up 3.1%

NASDAQ:CLBT traded up $0.34 during mid-day trading on Friday, hitting $11.14. 7,828,758 shares of the company traded hands, compared to its average volume of 2,139,398. The stock's fifty day moving average price is $14.52 and its 200-day moving average price is $14.05. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of 39.79, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18. Cellebrite DI has a one year low of $9.58 and a one year high of $19.98.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.05 by $0.06. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.The firm had revenue of $131.14 million for the quarter, compared to the consensus estimate of $131.87 million. Equities analysts predict that Cellebrite DI will post 0.41 EPS for the current year.

Insider Buying and Selling

In related news, CFO David Barter sold 41,734 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the sale, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas E. Hogan sold 139,713 shares of Cellebrite DI stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the sale, the chief executive officer directly owned 790,548 shares in the company, valued at $12,166,533.72. This trade represents a 15.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 297,934 shares of company stock worth $4,631,972. 5.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cellebrite DI

Several hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock worth $3,362,000 after acquiring an additional 24,881 shares during the last quarter. Geode Capital Management LLC grew its stake in Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company's stock valued at $5,029,000 after acquiring an additional 43,898 shares in the last quarter. Invesco Ltd. increased its holdings in Cellebrite DI by 6.4% in the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock valued at $56,089,000 after acquiring an additional 209,473 shares during the last quarter. First Trust Advisors LP bought a new stake in Cellebrite DI in the 2nd quarter valued at $341,000. Finally, Marshall Wace LLP purchased a new stake in Cellebrite DI in the 2nd quarter worth $4,472,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analysts continue to see upside despite reducing their estimates. JPMorgan lowered its price target from $20 to $16 while retaining an Overweight rating; D.A. Davidson cut its target from $22 to $15 but maintained Buy; and Needham reduced its target from $15 to $12.50 while also keeping a Buy rating. The revised targets remain above the recent trading level. Analyst price-target updates
• Positive Sentiment: Second-quarter adjusted EPS of $0.11 exceeded the commonly cited analyst estimate of $0.05, and subscription revenue continued to grow. Management also raised its adjusted EBITDA target, providing some support for profitability. Cellebrite earnings release
• Positive Sentiment: Unusually heavy call-option activity, with nearly 20,000 contracts traded versus average volume of about 586, suggests some traders are positioning for a rebound. This is a speculative signal rather than a change in fundamentals.
• Neutral Sentiment: Cellebrite completed a planned CEO succession, appointing Shiven Ramji to replace Thomas E. Hogan. The transition could lead to a strategic reset, but it also adds uncertainty as investors reassess the company’s growth plans. CEO succession announcement
• Negative Sentiment: The primary catalyst for the decline was weaker forward guidance. Third-quarter revenue is forecast at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. Cellebrite also reduced its 2026 annual recurring revenue outlook, signaling slower growth.
• Negative Sentiment: Revenue of $131.14 million slightly missed expectations of $131.87 million, and ARR reportedly fell short of prior guidance. The revenue and recurring-revenue misses outweighed the quarterly EPS beat. Cellebrite Q2 earnings analysis
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations and whether previous projections and disclosures were accurate. These are allegations, not findings, but they increase legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Outgoing CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. While the sale may reflect the leadership transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source